The Brain Tumor Symposium will present the most up-to-date research on brain tumors and the translational application of knowledge to design clinical trials, the most recent clinical trial outcomes data and its interpretation and application to clinical practice, and the innovations in surgical technique and technology. Recently, there have been exciting technical and technological advances in surgical therapy and newly FDA-approved drugs for the treatment of brain tumor patients. This data will be discussed in dedicated lecture formats and reinforced in case-based discussions.
Physicians and nursing staff whose practice includes adult brain tumor patients. Relevant specialty groups include neurological surgery, neurology (neuro-oncology), medical oncology, radiation oncology, rehabilitation/psychiatry, radiology.
Accreditation Statement :
The Northwestern University’s Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
The Northwestern University’s Feinberg School of Medicine designates this educational activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Accreditation Information:
Northwestern Memorial Hospital is an approved provider of continuing nursing education by the Illinois Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This program is approved for 6.0 contact hours.
· Examine the scientific rationale behind the development of the Velcade trial.
· Review the results of using 5-ALA for the resection of gliomas.
· Review the Stupp protocol – timing and dose of chemotherapy and radiation therapy.
· Interpret new clinical data of antiangiogenesis therapy.
· Discuss the radiographic changes that occur after initiating anti-angiogenesis therapy.
· Review the use and role of steroids and antiepileptic agents.
· Examine the appropriate methods of monitoring for systemic adverse events through the use of laboratory tests.
· Review the current clinical trial options.